Referencias
1. Bomprezzi R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord. 2015;8(1):20-30. DOI: 10.1177/1756285614564152.
2. Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl). 2016;6:7-32. DOI: 10.2147/PTT.S64950.
3. Grace PM, Gaudet AD, Staikopoulos V, Maier SF, Hutchinson MR, Salvemini D, et al. Nitroxidative Signaling Mechanisms in Pathological Pain. Trends Neurosci. 2016;39(12):862-79. DOI: 10.1016/j.tins.2016.10.003.
4. Satoh T, Okamoto SI, Cui J, Watanabe Y, Furuta K, Suzuki M, et al. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. Proc Natl Acad Sci U S A. 2006;103(3):768-73. DOI: 10.1073/pnas.0505723102.
5. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-72. DOI: 10.1016/S0140-6736(08)61619-0.
6. Patejdl R, Zettl UK. Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. Autoimmun Rev. 2017;16(9):925-36. DOI: 10.1016/j.autrev.2017.07.004.
7. Li J, Ma J, Lacagnina MJ, Lorca S, Odem MA, Walters ET, et al. Oral Dimethyl Fumarate Reduces Peripheral Neuropathic Pain in Rodents via NFE2L2 Antioxidant Signaling. Anesthesiology. 2020;132(2):343-56. DOI: 10.1097/ALN.0000000000003077. Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017;6(Suppl 1):25-33. DOI: 10.1007/s40122-017-0091-4.